Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
European Journal of Medicinal Chemistry
|
August 15, 2012
Synthesis, cytotoxicity of new 4-arylidene curcumin analogues and their multi-functions in inhibition of both NF-κB and Akt signalling
Yinglin Zuo, Jianing Huang, Binhua Zhou, et al.
Angewandte Chemie (International Ed. in English)
|
September 23, 2014
Chemical dynamic kinetic resolution and S/R interconversion of unprotected α-amino acids
Ryosuke Takeda, Akie Kawamura, Aki Kawashima, et al.
Chemosphere
|
February 22, 2023
Adsorption behavior of aniline pollutant on polystyrene microplastics
Zhenyu Chen, Jinchan Yang, Duanyi Huang, et al.
Journal of Medicinal Chemistry
|
February 24, 2022
Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors
Chunpu Li, Mingbo Su, Wei Zhu, et al.
European Journal of Medicinal Chemistry
|
June 20, 2021
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma
Shuni Wang, Hong Yang, Mingbo Su, et al.
Innovation (Cambridge (Mass.))
|
January 28, 2025
Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study
Luoyan Ai, Qian Li, Shilong Zhang, et al.
Journal for Immunotherapy of Cancer
|
February 22, 2024
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
Shengxiang Ren, Xicheng Wang, Bao-Hui Han, et al.
Cancer Immunology, Immunotherapy : CII
|
May 10, 2024
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study
Shengxiang Ren, Anwen Xiong, Jia Yu, et al.
Signal Transduction and Targeted Therapy
|
March 24, 2026
Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation
Jiang Wang, Hanlin Wang, Runhua Du, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2020
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Jianming Xu, Jie Shen, Shanzhi Gu, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
European Journal of Medicinal Chemistry
|
August 15, 2012
Synthesis, cytotoxicity of new 4-arylidene curcumin analogues and their multi-functions in inhibition of both NF-κB and Akt signalling
Yinglin Zuo, Jianing Huang, Binhua Zhou, et al.
Angewandte Chemie (International Ed. in English)
|
September 23, 2014
Chemical dynamic kinetic resolution and S/R interconversion of unprotected α-amino acids
Ryosuke Takeda, Akie Kawamura, Aki Kawashima, et al.
Chemosphere
|
February 22, 2023
Adsorption behavior of aniline pollutant on polystyrene microplastics
Zhenyu Chen, Jinchan Yang, Duanyi Huang, et al.
Journal of Medicinal Chemistry
|
February 24, 2022
Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors
Chunpu Li, Mingbo Su, Wei Zhu, et al.
European Journal of Medicinal Chemistry
|
June 20, 2021
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma
Shuni Wang, Hong Yang, Mingbo Su, et al.
Innovation (Cambridge (Mass.))
|
January 28, 2025
Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study
Luoyan Ai, Qian Li, Shilong Zhang, et al.
Journal for Immunotherapy of Cancer
|
February 22, 2024
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
Shengxiang Ren, Xicheng Wang, Bao-Hui Han, et al.
Cancer Immunology, Immunotherapy : CII
|
May 10, 2024
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study
Shengxiang Ren, Anwen Xiong, Jia Yu, et al.
Signal Transduction and Targeted Therapy
|
March 24, 2026
Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation
Jiang Wang, Hanlin Wang, Runhua Du, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2020
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Jianming Xu, Jie Shen, Shanzhi Gu, et al.
Page
of 4